These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
419 related articles for article (PubMed ID: 24785428)
1. The practical impact of altered dosing on perampanel plasma concentrations: pharmacokinetic modeling from clinical studies. Gidal BE; Majid O; Ferry J; Hussein Z; Yang H; Zhu J; Fain R; Laurenza A Epilepsy Behav; 2014 Jun; 35():6-12. PubMed ID: 24785428 [TBL] [Abstract][Full Text] [Related]
2. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures. Gidal BE; Ferry J; Majid O; Hussein Z Epilepsia; 2013 Aug; 54(8):1490-7. PubMed ID: 23772853 [TBL] [Abstract][Full Text] [Related]
3. Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters. Gidal BE; Maganti R; Laurenza A; Yang H; Verbel DA; Schuck E; Ferry J Epilepsy Res; 2017 Aug; 134():41-48. PubMed ID: 28535410 [TBL] [Abstract][Full Text] [Related]
4. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials. Yang H; Laurenza A; Williams B; Patten A; Hussein Z; Ferry J Epilepsy Res; 2015 Aug; 114():122-30. PubMed ID: 26088895 [TBL] [Abstract][Full Text] [Related]
5. Tolerability and safety of perampanel: two randomized dose-escalation studies. Krauss GL; Bar M; Biton V; Klapper JA; Rektor I; Vaiciene-Magistris N; Squillacote D; Kumar D Acta Neurol Scand; 2012 Jan; 125(1):8-15. PubMed ID: 21883097 [TBL] [Abstract][Full Text] [Related]
6. The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist. Patsalos PN Epilepsia; 2015 Jan; 56(1):12-27. PubMed ID: 25495693 [TBL] [Abstract][Full Text] [Related]
7. Analysis of pooled phase III trials of adjunctive perampanel for epilepsy: Impact of mechanism of action and pharmacokinetics on clinical outcomes. Kwan P; Brodie MJ; Laurenza A; FitzGibbon H; Gidal BE Epilepsy Res; 2015 Nov; 117():117-24. PubMed ID: 26448264 [TBL] [Abstract][Full Text] [Related]
8. Perampanel for epilepsy with partial-onset seizures: a pharmacokinetic and pharmacodynamic evaluation. Schulze-Bonhage A Expert Opin Drug Metab Toxicol; 2015; 11(8):1329-37. PubMed ID: 26111428 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, exposure-cognition, and exposure-efficacy relationships of perampanel in adolescents with inadequately controlled partial-onset seizures. Villanueva V; Majid O; Nabangchang C; Yang H; Laurenza A; Ferry J; Hussein Z Epilepsy Res; 2016 Nov; 127():126-134. PubMed ID: 27595590 [TBL] [Abstract][Full Text] [Related]
10. Absence of Liver Toxicity in Perampanel-Treated Subjects: Pooled results from partial seizure phase III perampanel clinical studies. Laurenza A; Yang H; Williams B; Zhou S; Ferry J Epilepsy Res; 2015 Jul; 113():76-85. PubMed ID: 25986193 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. French JA; Krauss GL; Steinhoff BJ; Squillacote D; Yang H; Kumar D; Laurenza A Epilepsia; 2013 Jan; 54(1):117-25. PubMed ID: 22905857 [TBL] [Abstract][Full Text] [Related]
12. Clinical profiles associated with serum perampanel concentrations in children with refractory epilepsy. Ishikawa N; Tateishi Y; Tani H; Kobayashi Y; Kobayashi M Epilepsy Behav; 2019 May; 94():82-86. PubMed ID: 30897534 [TBL] [Abstract][Full Text] [Related]
13. Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy. Gidal BE; Laurenza A; Hussein Z; Yang H; Fain R; Edelstein J; Kumar D; Ferry J Neurology; 2015 May; 84(19):1972-80. PubMed ID: 25878177 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Steinhoff BJ; Ben-Menachem E; Ryvlin P; Shorvon S; Kramer L; Satlin A; Squillacote D; Yang H; Zhu J; Laurenza A Epilepsia; 2013 Aug; 54(8):1481-9. PubMed ID: 23663001 [TBL] [Abstract][Full Text] [Related]
15. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Krauss GL; Serratosa JM; Villanueva V; Endziniene M; Hong Z; French J; Yang H; Squillacote D; Edwards HB; Zhu J; Laurenza A Neurology; 2012 May; 78(18):1408-15. PubMed ID: 22517103 [TBL] [Abstract][Full Text] [Related]
16. Changes in perampanel levels during de-induction: Simulations following carbamazepine discontinuation. Schuck E; Ferry J; Gidal B; Hussein Z Acta Neurol Scand; 2020 Aug; 142(2):131-138. PubMed ID: 32430908 [TBL] [Abstract][Full Text] [Related]
17. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Perucca E; Cloyd J; Critchley D; Fuseau E Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic simulations of topiramate plasma concentrations following dosing irregularities with extended-release vs. immediate-release formulations. Brittain ST; Wheless JW Epilepsy Behav; 2015 Nov; 52(Pt A):31-6. PubMed ID: 26409125 [TBL] [Abstract][Full Text] [Related]
19. Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307. Krauss GL; Perucca E; Ben-Menachem E; Kwan P; Shih JJ; Squillacote D; Yang H; Gee M; Zhu J; Laurenza A Epilepsia; 2013 Jan; 54(1):126-34. PubMed ID: 22905878 [TBL] [Abstract][Full Text] [Related]